SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0002 8703 OR L773:1097 6744 "

Sökning: L773:0002 8703 OR L773:1097 6744

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
61.
  •  
62.
  • Enhörning, Sofia, et al. (författare)
  • Copeptin is an independent predictor of diabetic heart disease and death.
  • 2015
  • Ingår i: American Heart Journal. - : Elsevier BV. - 1097-6744 .- 0002-8703. ; 169:4, s. 549-549
  • Tidskriftsartikel (refereegranskat)abstract
    • We previously discovered that high copeptin is associated with incidence of diabetes mellitus (diabetes), abdominal obesity, and albuminuria. Furthermore, copeptin predicts cardiovascular events after myocardial infarction in diabetic patients, but whether it is associated with heart disease and death in individuals without diabetes and prevalent cardiovascular disease is unknown. In this study, we aim to test whether plasma copeptin (copeptin), the C-terminal fragment of arginine vasopressin prohormone, predicts heart disease and death differentially in diabetic and nondiabetic individuals.
  •  
63.
  •  
64.
  •  
65.
  • Ezekowitz, Michael D., et al. (författare)
  • Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion : Rationale and design of the EMANATE trial
  • 2016
  • Ingår i: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 179, s. 59-68
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Stroke prevention in anticoagulation-nafve patients with atrial fibrillation undergoing cardioversion has not been systematically studied.Objective: To determine outcomes in anticoagulation-naive patients (defined as those receiving an anticoagulant for <48 hours during the index episode of atrial fibrillation) scheduled for cardioversion.Methods: This is a randomized, prospective, open-label, real-world study comparing apixaban to heparin plus warfarin. Early image-guided cardioversion is encouraged. For apixaban, the usual dose is 5 mg BID with a dose reduction to 2.5 mg BID if 2 of the following are present: age >80 years, weight <60 kg, or serum creatinine >1.5 mg/dL. If cardioversion is immediate, a single starting dose of 10 mg (or 5 mg if the dose is down-titrated) of apixaban is administered. Cardioversion may be attempted up to 90 days after randomization. Patients are followed up for 30 days after cardioversion or 90 days postrandomization if cardioversion is not performed within that timeframe. Outcomes are stroke, systemic embolization, major bleeds, clinically relevant nonmajor bleeding, and death, all adjudication-blinded.Statistics: The warfarin-naive cohort from the ARISTOTLE study was considered the closest data set to the patients being recruited into this study. The predicted incidence of stroke, systemic embolism, and major bleeding within 30 days after randomization was approximately 0.75%. To adequately power for a noninferiority trial, approximately 48,000 participants would be needed, a number in excess of feasibility. The figure of 1,500 patients was considered clinically meaningful and achievable.
  •  
66.
  • Ezekowitz, Michael D., et al. (författare)
  • Rationale and design of RE-LY : randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
  • 2009
  • Ingår i: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 157:5, s. 805-810
  • Tidskriftsartikel (refereegranskat)abstract
    • Vitamin K antagonists (VKAs) are effective for stroke prevention in patients with atrial fibrillation (AF) but are difficult to use. Dabigatran etexilate is a prodrug that is rapidly converted to the active direct thrombin inhibitor dabigatran. It is administered in a fixed dose without laboratory monitoring and is being compared with warfarin (international normalized ratio 2-3) in the RE-LY trial. Two doses of dabigatran (110 and 150 mg BID) are being evaluated. RE-LY is a phase 3, prospective, randomized, open-label multinational (44 countries) trial of patients with nonvalvular AF and at least 1 risk factor for stroke. Recruitment concluded with a total of 18,113 patients. Patients who were VKA-naive and experienced are included in balanced proportions. The primary outcome is stroke (including hemorrhagic) or systemic embolism. Safety outcomes are bleeding, liver function abnormalities, and other adverse events. Adjudication of end points is blinded to drug assignment. The trial is expected to accrue a minimum of 450 events with a minimum 1-year of follow-up. RE-LY is the largest AF stroke prevention trial yet undertaken. It is unique because it includes equal numbers of VKA-experienced and naive patients and evaluates 2 different dosages of dabigatran, which may allow tailoring of dosing to individual patient needs. The worldwide site distribution and broad range of stroke risk further increase the general applicability of the trial. Results are expected in 2009.
  •  
67.
  • Faxen, Jonas, et al. (författare)
  • Associations between rheumatoid arthritis, incident heart failure, and left ventricular ejection fraction
  • 2023
  • Ingår i: American Heart Journal. - : MOSBY-ELSEVIER. - 0002-8703 .- 1097-6744. ; 259, s. 42-51
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Rheumatoid arthritis (RA) is an independent risk factor for heart failure (HF). Yet, the association between RA and left ventricular ejection fraction (LVEF) in incident HF is not well studied, nor are outcomes of HF in RA by LVEF.Methods We identified incident HF patients between 2003 and 2018 through the Swedish Heart Failure Registry, enriched with data from national health registers. Using logistic regression, associations between a prior diagnosis of RA and LVEF among HF patients and vs age, sex, and geographical area matched general population controls without HF were assessed. Additionally, associations between HF with vs without a prior diagnosis of RA, by LVEF, and outcomes up to 5 years after HF diagnosis were investigated using Cox regression. LVEF was primarily dichotomized at 40% and secondarily categorized as <40%, 40% to 49%, and >50%. Covariates included demographics and cardiovascular comorbidities. Results Among 20,916 incident HF patients, 331 (1.6%) had RA vs 1,047/103,501 (1.0%) of HF-free controls. The odds ratio (OR) for RA was 1.4 (95% CI: 1.1-1.8) in LVEF<40% vs HF-free controls and 1.6 (95% CI: 1.3-2.0) in LVEF>40% vs HF-free controls. Among HF patients, RA was more common in HF with LVEF >40% (1.9%) vs LVEF<40% (1.3%), corresponding to OR 1.4 (95% CI: 1.1-1.7). No associations between RA and cardiovascular outcomes were observed across LVEF. An association between RA and all-cause mortality was observed only for patients with LVEF<40% (hazard ratio: 1.4; 95% CI: 1.1-1.8).Conclusions RA was independently associated with incident HF, particularly HF with LVEF>40%. RA did not associate with cardiovascular outcomes following HF diagnosis but was associated with increased risk of all-cause mortality in HF with LVEF<40%. (Am Heart J 2023;259:42-51.)
  •  
68.
  • Flather, Marcus D., et al. (författare)
  • Cluster-randomized trial to evaluate the effects of a quality improvement program on management of non-ST-elevation acute coronary syndromes : The European Quality Improvement Programme for Acute Coronary Syndromes (EQUIP-ACS)
  • 2011
  • Ingår i: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 162:4, s. 700-707.e1
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Registries have shown that quality of care for acute coronary syndromes (ACS) often falls below the standards recommended in professional guidelines. Quality improvement (QI) is a strategy to improve standards of clinical care for patients, but the efficacy of QI for ACS has not been tested in randomized trials. Methods We undertook a prospective, cluster-randomized, multicenter, multinational study to evaluate the efficacy of a QI program for ACS. Participating centers collected data on consecutive admissions for non-ST-elevation ACS for 4 months before the QI intervention and 3 months after. Thirty-eight hospitals in France, Italy, Poland, Spain, and the United Kingdom were randomized to receive the QI program or not, 19 in each group. We measured 8 in-hospital quality indicators (risk stratification, coronary angiography, anticoagulation, beta-blockers, statins, angiotensin-converting enzyme inhibitors, and clopidogrel loading and maintenance) before and after the intervention and compared composite changes between the QI and non-QI groups. Results A total of 2604 patients were enrolled. The absolute overall change in use of quality indicators in the QI group was 8.5% compared with 0.8% in the non-QI group (odds ratio for achieving a quality indicator in QI versus non-QI 1.66, 95% CI 1.43-1.94; P < .001). The main changes were observed in the use of risk stratification and clopidogrel loading dose. Conclusions The QI strategy resulted in a significant improvement in the quality indicators measured. This type of QI intervention can lead to useful changes in health care practice for ACS in a wide range of settings.
  •  
69.
  • Fogleman, Nicholas D., et al. (författare)
  • Regional variation in quality of life in patients with a Fontan circulation: A multinational perspective
  • 2017
  • Ingår i: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 193, s. 55-62
  • Tidskriftsartikel (refereegranskat)abstract
    • © 2017 Elsevier Inc. Background Impaired quality of life (QOL) is associated with congenital heart disease (CHD) and country of residence; however, few studies have compared QOL in patients with differing complexities of CHD across regional populations. The current study examined regional variation in QOL outcomes in a large multinational sample of patients with a Fontan relative to patients with atrial septal defects (ASDs) and ventricular septal defects (VSDs). Methods From the Assessment of Patterns of Patient-Reported Outcomes in Adults with Congenital Heart disease—International Study (APPROACH-IS), 405 patients (163 Fontan and 242 ASD/VSD) across Asia, Europe, and North America provided consent for access to their medical records and completed a survey evaluating QOL (0 to 100 linear analog scale). Primary CHD diagnosis, disease complexity, surgical history, and documented history of mood and anxiety disorders were recorded. Differences in QOL, medical complications, and mood and anxiety disorders between Fontan and ASD/VSD patients, and across geographic regions, were examined using analysis of covariance. Hierarchical regression analyses were conducted to identify variables associated with the QOL ratings. Results Patients with a Fontan reported significantly lower QOL, and greater medical complications and mood and anxiety disorders relative to patients with ASD/VSD. Inpatient cardiac admissions, mood disorders, and anxiety disorders were associated with lower QOL among patients with a Fontan, and mood disorders were associated with lower QOL among patients with ASD/VSD. Regional differences for QOL were not observed in patients with a Fontan; however, significant differences were identified in patients with ASD/VSD. Conclusions Regional variation of QOL is commonplace in adults with CHD; however, it appears affected by greater disease burden. Among patients with a Fontan, regional variation of QOL is lost. Specific attempts to screen for QOL and mood and anxiety disorders among CHD patients may improve the care of patients with the greatest disease burden.
  •  
70.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (355)
forskningsöversikt (2)
Typ av innehåll
refereegranskat (344)
övrigt vetenskapligt/konstnärligt (13)
Författare/redaktör
Wallentin, Lars (40)
Wallentin, Lars, 194 ... (33)
Lopes, Renato D. (27)
Granger, Christopher ... (22)
Alexander, John H. (21)
Erlinge, David (20)
visa fler...
James, Stefan K (20)
Held, Claes, 1956- (19)
Mahaffey, Kenneth W. (16)
Herlitz, Johan, 1949 (15)
Harrington, Robert A (15)
Armstrong, Paul W. (15)
James, Stefan, 1964- (14)
Lindahl, Bertil (14)
Oldgren, Jonas, 1964 ... (14)
James, Stefan K., 19 ... (14)
Dellborg, Mikael, 19 ... (12)
Storey, Robert F. (12)
Swedberg, Karl, 1944 (11)
Herlitz, Johan (11)
Lagerqvist, Bo (11)
Tricoci, Pierluigi (11)
Steg, Philippe Gabri ... (10)
James, Stefan (10)
White, Harvey D. (10)
Himmelmann, Anders (10)
Jernberg, T (9)
Huber, Kurt (9)
Pahlm, Olle (9)
Van de Werf, Frans (9)
Hijazi, Ziad (9)
Cannon, Christopher ... (9)
Siegbahn, Agneta (8)
Redfors, Björn (8)
Hanna, Michael (8)
Lindahl, Bertil, 195 ... (8)
Venge, Per (8)
Becker, Richard C. (8)
Janzon, Magnus (7)
Fröbert, Ole, 1964- (7)
Karlsson, Thomas, 19 ... (7)
Koul, Sasha (7)
Engstrøm, Thomas (7)
Wagner, Galen S (7)
Wojdyla, Daniel M. (7)
Vinereanu, Dragos (7)
Alfredsson, Joakim (7)
Cornel, Jan H. (7)
Held, Claes (7)
Lindbäck, Johan (7)
visa färre...
Lärosäte
Uppsala universitet (154)
Karolinska Institutet (132)
Göteborgs universitet (74)
Lunds universitet (54)
Linköpings universitet (37)
Högskolan i Borås (26)
visa fler...
Örebro universitet (15)
Umeå universitet (14)
Kungliga Tekniska Högskolan (2)
Linnéuniversitetet (2)
Högskolan Väst (1)
Mälardalens universitet (1)
Malmö universitet (1)
visa färre...
Språk
Engelska (357)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (190)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy